Spark Therapeutics, Inc. News
Novartis and Roche Have Expensive Drugs That Scare Away Competitors
A brief snapshot of some medical breakthroughs that are among the costliest in the world.
Sangamo Shares Soar as Hemophilia Drug Shows Promise
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.
Spark Therapeutics' Shares Misfire on Roche Acquisition Delay
Shares of Spark Therapeutics slide amid a second regulatory-related delay of its $4.3 billion deal with Swiss pharmaceuticals group Roche Holdings AG.
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
Roche plans to regroup on its $4.3 billion offer to buy Spark Therapeutics after failing to win enough Spark shareholder votes, or receiving U.S. regulatory approval.
Trading Roku Stock as Downgrades Sap Its Run to New Highs
Roku was hit with a pair of downgrades on Wednesday
Win, With or Without China: Cramer's 'Mad Money' Recap
Jim Cramer asks whether there aren't enough good things happening that we can sustain an advance without a China deal.
3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto
ETFs could see big inflows again and Sparks stock soars; these are among the important market items today.
Dow Closes Modestly Higher After Trump Extends China Tariff Deadline
The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.
Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts
Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.
Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know
U.S. stock futures rise after Donald Trump says he will delay increasing tariffs on China-made goods; Swiss drug giant Roche to buy Spark Therapeutics for about $4.8 billion; Warren Buffett wants to make an 'elephant-sized acquisition'; Kraft Heinz reportedly reviewing options for Maxwell House.
Is This Synthetic Biology Pioneer On The Right Track?
Amyris is showing progress in one key area, but it may not be enough.
'Pharma Bro' Martin Shkreli's Crypto Conversion Turns Sour
The disgraced investor and convicted felon launched a cryptocurrency last July after his release from prison.
Over 1.7 Million Fords And Lincolns Are At Risk Of Being Recalled
The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.